Every 10-Q that CalciMedica, Inc. (CALC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CALC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CALC filings page.
CalciMedica, Inc. reported second-quarter 2026 results as a clinical-stage biopharmaceutical company with no product revenue and an accumulated deficit of $192.0 million. For the quarter ended June 30, 2026, operating expenses fell to $4.0 million from $6.6 million a year earlier, reflecting lower research and development and general and administrative spending.
The company recorded a Q2 2026 net loss of $7.7 million compared with $6.0 million in Q2 2025, driven partly by a $3.6 million noncash loss from changes in fair value of financial instruments. For the first six months of 2026, net loss was $2.7 million versus $11.0 million in the prior-year period, largely due to favorable fair value movements earlier in the year.
Cash and cash equivalents increased to $18.6 million at June 30, 2026 from $11.5 million at year-end, primarily from a June PIPE financing and at-the-market sales providing $15.0 million gross proceeds. Total liabilities decreased to $14.0 million, while stockholders’ equity improved from a deficit of $(6.6) million to positive equity of $5.5 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without additional capital, given projected operating needs and a $9.2 million fair-valued promissory note and $1.3 million warrant liability on the balance sheet.
CalciMedica, Inc. filed its Q3 2025 report, detailing ongoing operating losses and liquidity pressure. The company reported a net loss of $7.804 million for the quarter and $18.802 million for the nine months ended September 30, 2025. Operating expenses were $5.618 million in Q3, led by research and development of $3.851 million.
As of September 30, 2025, cash and cash equivalents were $5.470 million and short‑term investments were $8.614 million. Management states there is substantial doubt about the company’s ability to continue as a going concern. The balance sheet shows a stockholders’ deficit of $268 thousand, a promissory note at fair value of $8.900 million, and a warrant liability of $2.600 million.
The company funded $10.0 million under a loan on February 28, 2025, bearing interest at the greater of 5.00% + prime or 12.75%, maturing on September 1, 2028. During 2025, it raised additional equity via its ATM program, selling 760,130 shares for net proceeds of $1.761 million through September 30. Shares outstanding were 14,409,431 as of November 6, 2025.